FDA Approved: UBRELVY — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved Allergan's supplemental application for UBRELVY (ubrogepant), resulting in a label update for its use in treating acute migraine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Ubrelvy (ubrogepant)

Snippet

SUPPL AP for UBRELVY (UBROGEPANT)